Quoin Pharmaceuticals (QNRX)

Executive Summary

Quoin Pharmaceuticals (NASDAQ: QNRX) is a clinical-stage biopharmaceutical company developing novel topical therapies for severe rare dermatological conditions. Its lead candidate, QRX003 (topical rapamycin), is in Phase 2/3 trials for Netherton Syndrome (NS), a debilitating genetic disorder with no approved therapies. The company leverages proprietary formulation technology to repurpose known compounds, aiming to address significant unmet need. Quoin is targeting a 2027 FDA approval for QRX003 and has built a hybrid commercial strategy to ensure global patient access. With a market valuation of ~$11 million, the company represents a high-risk, high-reward opportunity in the rare disease space. Quoin is currently conducting three Phase 2/3 trials for QRX003 in NS: two actively recruiting (NCT06953466, NCT05789056) and one active (NCT05521438). The near-term catalyst is the completion of trial NCT06953466 in July 2026, with top-line data expected shortly thereafter. Additionally, the company is on track to complete the pivotal trial NCT05521438 by December 2026, which could support a future NDA submission. Beyond QRX003, Quoin's pipeline includes earlier-stage programs for other rare skin conditions. The company's success hinges on positive data from these trials, regulatory engagement, and its ability to secure non-dilutive funding or partnerships to support commercialization.

Upcoming Catalysts (preview)

• Q3 2026Top-line data from QRX003 Phase 2/3 trial (NCT06953466) in Netherton Syndrome65% success
• Q4 2026Completion of pivotal Phase 2/3 trial (NCT05521438) for QRX00370% success
• Q1 2027Pre-NDA meeting or regulatory update for QRX00350% success